Indicator type;Size of the company;Total
Number of companies carrying out R&D in Biotechnology;Less than 250 employees;1.221
Number of companies carrying out R&D in Biotechnology;250 and more employees;156
Number of companies carrying out R&D in Biotechnology;Total;1.376
% Companies by type of biotechnology used: Genetic Code;Less than 250 employees;30,2
% Companies by type of biotechnology used: Genetic Code;250 and more employees;41,5
% Companies by type of biotechnology used: Genetic Code;Total;31,4
% Companies by type of biotechnology used: Functional Units;Less than 250 employees;42,4
% Companies by type of biotechnology used: Functional Units;250 and more employees;54,3
% Companies by type of biotechnology used: Functional Units;Total;43,7
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Less than 250 employees;21,2
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;250 and more employees;35,9
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Total;22,8
% Companies by type of biotechnology used: Bioprocesses;Less than 250 employees;46,1
% Companies by type of biotechnology used: Bioprocesses;250 and more employees;65,3
% Companies by type of biotechnology used: Bioprocesses;Total;48,3
% Companies by type of biotechnology used: Subcellular Organisms;Less than 250 employees;7
% Companies by type of biotechnology used: Subcellular Organisms;250 and more employees;14,6
% Companies by type of biotechnology used: Subcellular Organisms;Total;7,9
% Companies by type of biotechnology used: Bioinformatics;Less than 250 employees;26,5
% Companies by type of biotechnology used: Bioinformatics;250 and more employees;32,5
% Companies by type of biotechnology used: Bioinformatics;Total;27,1
% Companies by type of biotechnology used: Nanobiotechnology;Less than 250 employees;11
% Companies by type of biotechnology used: Nanobiotechnology;250 and more employees;13,4
% Companies by type of biotechnology used: Nanobiotechnology;Total;11,2
% Companies by type of biotechnology used: Other;Less than 250 employees;18,1
% Companies by type of biotechnology used: Other;250 and more employees;14
% Companies by type of biotechnology used: Other;Total;17,6
Companies in which biotechnology activities are: Main and/or exclusive;Less than 250 employees;686
Companies in which biotechnology activities are: Main and/or exclusive;250 and more employees;25
Companies in which biotechnology activities are: Main and/or exclusive;Total;711
Companies in which biotechnology activities are: A secondary business line;Less than 250 employees;214
Companies in which biotechnology activities are: A secondary business line;250 and more employees;55
Companies in which biotechnology activities are: A secondary business line;Total;270
Companies in which biotechnology activities are: A necessary tool for production;Less than 250 employees;320
Companies in which biotechnology activities are: A necessary tool for production;250 and more employees;75
Companies in which biotechnology activities are: A necessary tool for production;Total;395
% Companies by final application areas of biotechnology use: Human Health;Less than 250 employees;48,7
% Companies by final application areas of biotechnology use: Human Health;250 and more employees;42,7
% Companies by final application areas of biotechnology use: Human Health;Total;48
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Less than 250 employees;16,7
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;250 and more employees;17,9
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Total;16,9
% Companies by final application areas of biotechnology use: Food Products;Less than 250 employees;28
% Companies by final application areas of biotechnology use: Food Products;250 and more employees;40,1
% Companies by final application areas of biotechnology use: Food Products;Total;29,4
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Less than 250 employees;26,1
% Companies by final application areas of biotechnology use: Agriculture and Forestry;250 and more employees;22,6
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Total;25,7
% Companies by final application areas of biotechnology use: Environment;Less than 250 employees;17,9
% Companies by final application areas of biotechnology use: Environment;250 and more employees;18,9
% Companies by final application areas of biotechnology use: Environment;Total;18
% Companies by final application areas of biotechnology use: Industry;Less than 250 employees;12,6
% Companies by final application areas of biotechnology use: Industry;250 and more employees;16,5
% Companies by final application areas of biotechnology use: Industry;Total;13
R&D personnel in Biotechnology (PP);Less than 250 employees;10.421
R&D personnel in Biotechnology (PP);250 and more employees;6.836
R&D personnel in Biotechnology (PP);Total;17.257
R&D personnel in Biotechnology (PP): Research personnel;Less than 250 employees;6.087
R&D personnel in Biotechnology (PP): Research personnel;250 and more employees;3.108
R&D personnel in Biotechnology (PP): Research personnel;Total;9.195
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Less than 250 employees;4.333
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;250 and more employees;3.728
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Total;8.061
R&D personnel in Biotechnology (PP). Women;Less than 250 employees;5.700
R&D personnel in Biotechnology (PP). Women;250 and more employees;4.280
R&D personnel in Biotechnology (PP). Women;Total;9.980
R&D personnel in Biotechnology (PP). Women: Research personnel;Less than 250 employees;3.359
R&D personnel in Biotechnology (PP). Women: Research personnel;250 and more employees;1.863
R&D personnel in Biotechnology (PP). Women: Research personnel;Total;5.222
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Less than 250 employees;2.341
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;250 and more employees;2.417
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Total;4.758
R&D personnel in Biotechnology (FTE);Less than 250 employees;7.562,8
R&D personnel in Biotechnology (FTE);250 and more employees;5.320,6
R&D personnel in Biotechnology (FTE);Total;12.883,4
R&D personnel in Biotechnology (FTE): Research personnel;Less than 250 employees;4.665,3
R&D personnel in Biotechnology (FTE): Research personnel;250 and more employees;2.437,9
R&D personnel in Biotechnology (FTE): Research personnel;Total;7.103,2
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Less than 250 employees;2.897,4
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;250 and more employees;2.882,8
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Total;5.780,2
R&D personnel in Biotechnology (FTE). Women;Less than 250 employees;4.222
R&D personnel in Biotechnology (FTE). Women;250 and more employees;3.378,6
R&D personnel in Biotechnology (FTE). Women;Total;7.600,6
R&D personnel in Biotechnology (FTE). Women: Research personnel;Less than 250 employees;2.605,7
R&D personnel in Biotechnology (FTE). Women: Research personnel;250 and more employees;1.451,3
R&D personnel in Biotechnology (FTE). Women: Research personnel;Total;4.057
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Less than 250 employees;1.616,3
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;250 and more employees;1.927,3
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Total;3.543,7
Expenditure on internal R&D in Biotechnology (thousands of euros);Less than 250 employees;794.091
Expenditure on internal R&D in Biotechnology (thousands of euros);250 and more employees;489.255
Expenditure on internal R&D in Biotechnology (thousands of euros);Total;1.283.346
1) By type of expenditure: Current expenditure;Less than 250 employees;715.652
1) By type of expenditure: Current expenditure;250 and more employees;464.535
1) By type of expenditure: Current expenditure;Total;1.180.187
1.1) Labour expenditure of research personnel;Less than 250 employees;235.238
1.1) Labour expenditure of research personnel;250 and more employees;137.183
1.1) Labour expenditure of research personnel;Total;372.421
1.2) Labour expenditure of technical and auxiliary personnel;Less than 250 employees;113.075
1.2) Labour expenditure of technical and auxiliary personnel;250 and more employees;116.659
1.2) Labour expenditure of technical and auxiliary personnel;Total;229.734
1.3) Other current expenditure;Less than 250 employees;367.339
1.3) Other current expenditure;250 and more employees;210.693
1.3) Other current expenditure;Total;578.032
2) By type of expenditure: Capital expenditure;Less than 250 employees;78.439
2) By type of expenditure: Capital expenditure;250 and more employees;24.720
2) By type of expenditure: Capital expenditure;Total;103.159
2.1) Land and buildings;Less than 250 employees;8.547
2.1) Land and buildings;250 and more employees;2.342
2.1) Land and buildings;Total;10.889
2.2) Equipment and tools;Less than 250 employees;40.395
2.2) Equipment and tools;250 and more employees;18.809
2.2) Equipment and tools;Total;59.204
2.3) Acquisition of specific R&D software;Less than 250 employees;4.415
2.3) Acquisition of specific R&D software;250 and more employees;1.208
2.3) Acquisition of specific R&D software;Total;5.623
2.4) Other R&D-specific IP products;Less than 250 employees;25.082
2.4) Other R&D-specific IP products;250 and more employees;2.360
2.4) Other R&D-specific IP products;Total;27.442
1.1) By origin of funds: Own funds;Less than 250 employees;548.276
1.1) By origin of funds: Own funds;250 and more employees;339.251
1.1) By origin of funds: Own funds;Total;887.527
1.2) By origin of funds: Funds from the Business sector;Less than 250 employees;96.237
1.2) By origin of funds: Funds from the Business sector;250 and more employees;47.667
1.2) By origin of funds: Funds from the Business sector;Total;143.903
1.3) By origin of funds: Funds from the Public Administration sector;Less than 250 employees;98.923
1.3) By origin of funds: Funds from the Public Administration sector;250 and more employees;27.623
1.3) By origin of funds: Funds from the Public Administration sector;Total;126.546
1.4) By origin of funds: Funds from the Higher Education sector;Less than 250 employees;94
1.4) By origin of funds: Funds from the Higher Education sector;250 and more employees;0
1.4) By origin of funds: Funds from the Higher Education sector;Total;94
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Less than 250 employees;2.684
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;250 and more employees;9.939
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Total;12.623
1.6) By origin of funds: Funds from the rest of the world;Less than 250 employees;47.877
1.6) By origin of funds: Funds from the rest of the world;250 and more employees;64.776
1.6) By origin of funds: Funds from the rest of the world;Total;112.652
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Less than 250 employees;76.773
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);250 and more employees;60.659
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Total;137.432
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Less than 250 employees;38.607
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;250 and more employees;49.521
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Total;88.127
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Less than 250 employees;38.166
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;250 and more employees;11.139
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Total;49.305
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Less than 250 employees;46,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;250 and more employees;23,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Total;43,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Less than 250 employees;16,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;250 and more employees;15,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Total;16,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Less than 250 employees;24,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;250 and more employees;16
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Total;23,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Less than 250 employees;14,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;250 and more employees;14,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Total;14,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Less than 250 employees;19
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;250 and more employees;10,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Total;18,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Less than 250 employees;20,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;250 and more employees;12,9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Total;19,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Less than 250 employees;18,9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;250 and more employees;21,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Total;19,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Less than 250 employees;51
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;250 and more employees;40,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Total;49,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Less than 250 employees;61
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;250 and more employees;46,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Total;59,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Less than 250 employees;23,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;250 and more employees;11
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Total;22,3
% Companies with international revenues related to biotechnology activities;Less than 250 employees;23,6
% Companies with international revenues related to biotechnology activities;250 and more employees;22,7
% Companies with international revenues related to biotechnology activities;Total;23,6
% Companies representing international revenues related to biotechnology activities;Less than 250 employees;6,9
% Companies representing international revenues related to biotechnology activities;250 and more employees;1
% Companies representing international revenues related to biotechnology activities;Total;1,5
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Less than 250 employees;50
% International revenues related to biotechnology activities distributed in: Revenues from the EU;250 and more employees;62,8
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Total;57,6
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Less than 250 employees;50
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;250 and more employees;37,2
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Total;42,4
% International revenues related to biotechnology activities by classification: International trade in goods and services;Less than 250 employees;91,4
% International revenues related to biotechnology activities by classification: International trade in goods and services;250 and more employees;76,2
% International revenues related to biotechnology activities by classification: International trade in goods and services;Total;82,3
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Less than 250 employees;4,5
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 and more employees;20,6
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;14,1
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Less than 250 employees;1
% International revenues related to biotechnology activities by classification: Subsidies from external sources;250 and more employees;1,8
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Total;1,5
% International revenues related to biotechnology activities by classification: Other;Less than 250 employees;3,1
% International revenues related to biotechnology activities by classification: Other;250 and more employees;1,4
% International revenues related to biotechnology activities by classification: Other;Total;2,1